Connect with us

Business

Share, Euro Shifts Examined as Greek Business Deal Awaited

Published

on

Global shares and the Euro balanced on Tuesday November 20th 2012, after an early drop in response to France losing its greatest credit ranking from Moody’s, with the market shares sustaining acute profits from the earlier day as shareholders look forward to a major business contract for Greece.

The finance ministers of the Euro region and the IMF (International Monetary Fund) are to gather during the later part of the day, and are anticipated to endorse a program to present Greece nearly $56.4-billion (44-billion Euros) in financial assistance by 5th December, which is required to totally avoid bankruptcy.

The expected solution of the short-range funding issues for Greece, and confidence that the policymakers of the United States would arrive at a new business deal to turn away automatic tax increase and spending reductions have been well behind a quick march in riskier resources during this week.

The world equity market index of MSCI advanced by nearly 2-percent recently on Monday November 19th 2012 to record its best day performance ever since 27th July, and detained onto those profits by the mid-market session on November 20th 2012 Tuesday to be practically unaltered at nearly 326.60-points.

The stock futures of the United States indicated a marginal retracement when exchanging recommences on Wall Street, but this arrives after the open Standard & Poor 500 market index added nearly 2-percent during the previous 2 market sessions. Concentration in the U.S. market is expected to be resolutely concentrated on attempts by Congress to arrive at a possible negotiation to prevent nearly $600-billion in tax hikes, and spending reductions expected to begin during January, broadly stated as the looming fiscal cliff.

Recently, a leading market analyst at IG Markets, Brenda Kelly said that the fiscal cliff will be the major headline in the coming days, and that is expected to guide the markets for the next few days, especially with a small week in the United States. On Thursday i.e. November 22nd 2012, the markets of the United States are expected to close as it will be a general Thanksgiving holiday.

Shareholders are also eagerly waiting to hear from the Chairman of the Federal Reserve- Ben Bernanke who will talk facing the Economic Association of the New York City, as he may present new insight in the fed’s enthusiasm for additional monetary stimulus. In the euro zone, a broadly expected decision by Moody’s to slash the standard triple-A ranking of the 2nd biggest economy of Europe by 1-notch, and maintain it on a negative prospect provoked some initial trading in both single currency, and equity markets.

Business

Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)

Published

on

By

Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.

Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

Continue Reading

Biotech

Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)

Published

on

Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading

Biotech

Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)

Published

on

Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading
Advertisement

Trending